Entia develops patented, pharmaceutical-grade organic compounds, including one known as ErgoD2. Entia believes that ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. Entia's goal is to clinically validate and commercialize ErgoD2 through the prescription Medical Food and OTC Supplement channels.